Ser357

Site Information
SAssGPCsPAAPHPP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23105426

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	leukemia ( 4 ) , chronic myelogenous leukemia ( 4 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:	H2009 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , HeLa (cervical) ( 1 ) , K562 (erythroid) ( 2 , 4 ) , NCI-H157 (pulmonary) ( 3 ) , NCI-H1666 (pulmonary) ( 3 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
3	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
4	Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info